Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141 XCR1 dendritic cells

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • K. M. Silk
  • J. D. Silk
  • N. Ichiryu
  • T. J. Davies
  • A. J. Leishman
  • L. Carpenter
  • S. M. Watt
  • V. Cerundolo
  • P. J. Fairchild


Monocyte-derived dendritic cells (moDC) have been widely used in cancer immunotherapy but show significant donor-to-donor variability and low capacity for the cross-presentation of tumour-associated antigens (TAA) to CD8 T cells, greatly limiting the success of this approach. Given recent developments in induced pluripotency and the relative ease with which induced pluripotent stem (iPS) cell lines may be generated from individuals, we have succeeded in differentiating dendritic cells (DC) from human leukocyte antigen (HLA)-A 0201 iPS cells (iPS cell-derived DC (ipDC)), using protocols compliant with their subsequent clinical application. Unlike moDC, a subset of ipDC was found to coexpress CD141 and XCR1 that have been shown previously to define the human equivalent of mouse CD8α DC, in which the capacity for cross-presentation has been shown to reside. Accordingly, ipDC were able to cross-present the TAA, Melan A, to a CD8 T-cell clone and stimulate primary Melan A-specific responses among naïve T cells from an HLA-A 0201 donor. Given that CD141 XCR1 DC are present in peripheral blood in trace numbers that preclude their clinical application, the ability to generate a potentially unlimited source from iPS cells offers the possibility of harnessing their capacity for cross-priming of cytotoxic T lymphocytes for the induction of tumour-specific immune responses. © 2012 Macmillan Publishers Limited All rights reserved.

Bibliographical metadata

Original languageEnglish
Pages (from-to)1035-1040
Number of pages5
JournalGene Therapy
Issue number10
Publication statusPublished - Oct 2012